NCT00253500View on ClinicalTrials.gov

Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

September 30, 2005

Study Completion Date

December 31, 2010

Conditions
Breast Cancer
Interventions
BIOLOGICAL

pegfilgrastim

6 mg in a syringe

DRUG

epirubicin hydrochloride

120 MG q 2 weeks for 4 cycles

PROCEDURE

conventional surgery

to remove small piece of cancer

Trial Locations (1)

44195-9001

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT00253500 - Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | Biotech Hunter | Biotech Hunter